

Jordan M Cloyd

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3532157/publications.pdf>

Version: 2024-02-01

175
papers

4,931
citations

101384

36
h-index

138251

58
g-index

175
all docs

175
docs citations

175
times ranked

5251
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient Perspectives on Defining Textbook Outcomes Following Major Abdominal Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 197-205.	0.9	11
2	Prognostic Significance of Preoperative Tumor Markers in Pseudomyxoma Peritonei from Low-Grade Appendiceal Mucinous Neoplasm: a Study from the US HIPEC Collaborative. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 414-424.	0.9	3
3	Impact of care fragmentation on the outcomes of patients receiving neoadjuvant and adjuvant therapy for pancreatic adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2022, 125, 185-193.	0.8	11
4	Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma. <i>Hpb</i> , 2022, 24, 833-840.	0.1	3
5	Outcomes of aborted cancer surgery: a call for patient-centered research. <i>Supportive Care in Cancer</i> , 2022, 30, 1907-1910.	1.0	8
6	Surgical treatment of hepatic oligometastatic pancreatic ductal adenocarcinoma: An analysis of the National Cancer Database. <i>Surgery</i> , 2022, 171, 1464-1470.	1.0	15
7	Rates and Outcomes of Aborted Cancer Surgery among Older Patients with Pancreatic Cancer: a SEER-Medicare Study. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1957-1959.	0.9	3
8	Association of County-Level Upward Economic Mobility with Stage at Diagnosis and Receipt of Curative-Intent Treatment among Patients with Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2022, 29, 5177-5185.	0.7	4
9	Predicting Novel Drug Candidates for Pancreatic Neuroendocrine Tumors via Gene Signature Comparison and Connectivity Mapping. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1670-1678.	0.9	5
10	Burnout Assessment Among Surgeons and Surgical Trainees During the COVID-19 Pandemic: A Systematic Review. <i>Journal of Surgical Education</i> , 2022, 79, 1206-1220.	1.2	14
11	Is CRS-HIPEC Still Indicated in Patients With Extraperitoneal Disease?. <i>Journal of Surgical Research</i> , 2022, 277, 269-278.	0.8	0
12	Development and Validation of an Explainable Machine Learning Model for Major Complications After Cytoreductive Surgery. <i>JAMA Network Open</i> , 2022, 5, e2212930.	2.8	13
13	Comparing Minimally Invasive and Open Pancreaticoduodenectomy for the Treatment of Pancreatic Cancer: a Win Ratio Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2022, 26, 1697-1704.	0.9	3
14	Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study. <i>World Journal of Gastrointestinal Oncology</i> , 2022, 14, 1175-1186.	0.8	5
15	Novel Drug Candidate Prediction for Intrahepatic Cholangiocarcinoma via Hub Gene Network Analysis and Connectivity Mapping. <i>Cancers</i> , 2022, 14, 3284.	1.7	11
16	County-Level Variation in Utilization of Surgical Resection for Early-Stage Hepatopancreatic Cancer Among Medicare Beneficiaries in the USA. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1736-1744.	0.9	3
17	Travel Patterns among Patients Undergoing Hepatic Resection in California: Does Driving Further for Care Improve Outcomes?. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 1471-1478.	0.9	5
18	Comparison of lymph node evaluation and yield among patients undergoing open and minimally invasive surgery for gallbladder adenocarcinoma. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2021, 35, 2223-2228.	1.3	11

#	ARTICLE	IF	CITATIONS
19	A novel preoperative risk score to optimize patient selection for performing concomitant liver resection with cytoreductive surgery/HIPEC. <i>Journal of Surgical Oncology</i> , 2021, 123, 187-195.	0.8	4
20	ASO Author Reflections: Refining the Surgical Management of Pancreatic Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2021, 28, 1050-1051.	0.7	0
21	Patient experience and quality of life during neoadjuvant therapy for pancreatic cancer: a systematic review and study protocol. <i>Supportive Care in Cancer</i> , 2021, 29, 3009-3016.	1.0	11
22	Inter-surgeon variability is associated with likelihood to undergo minimally invasive hepatectomy and postoperative mortality. <i>Hpb</i> , 2021, 23, 840-846.	0.1	1
23	A multi-institutional analysis of Textbook Outcomes among patients undergoing cytoreductive surgery for peritoneal surface malignancies. <i>Surgical Oncology</i> , 2021, 37, 101492.	0.8	15
24	The Role of Hyperthermic Intraperitoneal Chemotherapy for Non-colorectal Peritoneal Surface Malignancies. <i>Journal of Gastrointestinal Surgery</i> , 2021, 25, 303-318.	0.9	4
25	The Landmark Series: Pancreatic Neuroendocrine Tumors. <i>Annals of Surgical Oncology</i> , 2021, 28, 1039-1049.	0.7	18
26	Impact of Perioperative Blood Transfusions on Outcomes After Hyperthermic Intraperitoneal Chemotherapy: A Propensity-Matched Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 4499-4507.	0.7	10
27	Predicting post-operative pancreatic fistula: one size may not fit all. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 113-115.	0.7	3
28	Neoadjuvant therapy versus surgery first for ampullary carcinoma: A propensity score-matched analysis of the NCDB. <i>Journal of Surgical Oncology</i> , 2021, 123, 1558-1567.	0.8	11
29	National Trends in the Use of Neoadjuvant Therapy Before Cancer Surgery in the US From 2004 to 2016. <i>JAMA Network Open</i> , 2021, 4, e211031.	2.8	18
30	Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2021, 123, 1432-1440.	0.8	20
31	High Social Vulnerability and "Textbook Outcomes" after Cancer Operation. <i>Journal of the American College of Surgeons</i> , 2021, 232, 351-359.	0.2	95
32	Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic cancer. <i>Radiotherapy and Oncology</i> , 2021, 158, 207-214.	0.3	13
33	Neoadjuvant chemotherapy in bladder cancer: Clinical benefit observed in prospective trials computed with restricted mean survival times. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 435.e17-435.e22.	0.8	2
34	Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care. <i>World Journal of Gastroenterology</i> , 2021, 27, 4383-4394.	1.4	9
35	Variation in outcomes across surgeons meeting the Leapfrog volume standard for complex oncologic surgery. <i>Cancer</i> , 2021, 127, 4059-4071.	2.0	10
36	Is Textbook Oncologic Outcome a Valid Hospital-Quality Metric after High-Risk Surgical Oncology Procedures?. <i>Annals of Surgical Oncology</i> , 2021, 28, 8028-8045.	0.7	30

#	ARTICLE	IF	CITATIONS
37	Aging in Place: Estimating the Impact of Unexpected Intensive Care Unit Admission on Long-Term Functional Outcomes of Older Adults after Major Cancer Surgery. <i>Annals of Surgical Oncology</i> , 2021, 28, 6920-6922.	0.7	1
38	Trends in the use of adjuvant therapy for resected intrahepatic cholangiocarcinoma: getting ahead of the data. <i>Hepatobiliary Surgery and Nutrition</i> , 2021, 10, 515-517.	0.7	1
39	Metastatic disease to the liver: Locoregional therapy strategies and outcomes. <i>World Journal of Clinical Oncology</i> , 2021, 12, 725-745.	0.9	9
40	Neoadjuvant chemotherapy for colorectal liver metastases: A contemporary review of the literature. <i>World Journal of Gastrointestinal Oncology</i> , 2021, 13, 1043-1061.	0.8	21
41	Who Will Benefit? Using Radiomics to Predict Response to Oxaliplatin-Based Chemotherapy in Patients with Colorectal Liver Metastases. <i>Annals of Surgical Oncology</i> , 2021, 28, 2931-2933.	0.7	2
42	Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles. <i>Journal of Clinical Medicine</i> , 2021, 10, 104.	1.0	24
43	Hepatobiliary Cancers, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 541-565.	2.3	477
44	Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. <i>Cancers</i> , 2021, 13, 5168.	1.7	1
45	Insurance Coverage Type Impacts Hospitalization Patterns Among Patients with Hepatopancreatic Malignancies. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 1320-1329.	0.9	10
46	Textbook Outcomes Among Medicare Patients Undergoing Hepatopancreatic Surgery. <i>Annals of Surgery</i> , 2020, 271, 1116-1123.	2.1	158
47	Comprehensive Complication Index Validates Improved Outcomes Over Time Despite Increased Complexity in 3707 Consecutive Hepatectomies. <i>Annals of Surgery</i> , 2020, 271, 724-731.	2.1	50
48	Significance of Cancer Cells at the Vein Edge in Patients with Pancreatic Adenocarcinoma Following Pancreatectomy with Vein Resection. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 368-379.	0.9	14
49	Advances in the Diagnosis and Treatment of Patients with Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 552-560.	0.7	25
50	Should We Be Doing Cytoreductive Surgery with HIPEC for Signet Ring Cell Appendiceal Adenocarcinoma? A Study from the US HIPEC Collaborative. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 155-164.	0.9	27
51	Preoperative Risk Score for Predicting Incomplete Cytoreduction: A 12-Institution Study from the US HIPEC Collaborative. <i>Annals of Surgical Oncology</i> , 2020, 27, 156-164.	0.7	13
52	ASO Author Reflections: Impact of Operative Technique on Anastomotic Failure During Cytoreductive Surgery for Peritoneal Malignancies—Surgeon Preference is Fine. <i>Annals of Surgical Oncology</i> , 2020, 27, 793-794.	0.7	0
53	Predictors of Anastomotic Failure After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Does Technique Matter?. <i>Annals of Surgical Oncology</i> , 2020, 27, 783-792.	0.7	20
54	Routine Intensive Care Unit Admission Following Liver Resection: What Is the Value Proposition?. <i>Journal of Gastrointestinal Surgery</i> , 2020, 24, 2491-2499.	0.9	8

#	ARTICLE	IF	CITATIONS
55	Trends in the indications for and short-term outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy. American Journal of Surgery, 2020, 219, 478-483.	0.9	39
56	Complex hepato-pancreato-biliary caseload during general surgery residency training: are we adequately training the next generation?. Hpb, 2020, 22, 603-610.	0.1	8
57	Readmissions After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: a US HIPEC Collaborative Study. Journal of Gastrointestinal Surgery, 2020, 24, 165-176.	0.9	26
58	New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors. Expert Opinion on Pharmacotherapy, 2020, 21, 183-191.	0.9	9
59	Neoadjuvant Therapy Versus Immediate Surgery for Resectable Pancreas Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 752-754.	0.6	3
60	CRS/HIPEC with Major Organ Resection in Peritoneal Mesothelioma Does not Impact Major Complications or Overall Survival: A Retrospective Cohort Study of the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 4996-5004.	0.7	8
61	Implications of Postoperative Complications for Survival After Cytoreductive Surgery and HIPEC: A Multi-Institutional Analysis of the US HIPEC Collaborative. Annals of Surgical Oncology, 2020, 27, 4980-4995.	0.7	15
62	Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers, 2020, 12, 1914.	1.7	72
63	Neuroendocrine liver metastases: a contemporary review of treatment strategies. Hepatobiliary Surgery and Nutrition, 2020, 9, 440-451.	0.7	37
64	Analysis of textbook outcomes among patients undergoing resection of retroperitoneal sarcoma: A multi-institutional analysis of the US Sarcoma Collaborative. Journal of Surgical Oncology, 2020, 122, 1189-1198.	0.8	19
65	The impact of HIPEC vs. EPIC for the treatment of mucinous appendiceal carcinoma: a study from the US HIPEC collaborative. International Journal of Hyperthermia, 2020, 37, 1182-1188.	1.1	5
66	A Cross-Sectional Evaluation of Quality of Life Among Patients with Hepatic Adenomas. Journal of Gastrointestinal Surgery, 2020, 24, 2862-2864.	0.9	1
67	Impact of visitor restriction rules on the postoperative experience of COVID-19 negative patients undergoing surgery. Surgery, 2020, 168, 770-776.	1.0	53
68	Neoadjuvant modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Cancer Medicine, 2020, 9, 4711-4723.	1.3	28
69	The Landmark Series: Intrahepatic Cholangiocarcinoma. Annals of Surgical Oncology, 2020, 27, 2859-2865.	0.7	16
70	Outcomes of neoadjuvant chemotherapy before CRS+HIPEC for patients with appendiceal cancer. Journal of Surgical Oncology, 2020, 122, 388-398.	0.8	11
71	The Intersection of Age and Tumor Biology with Postoperative Outcomes in Patients After Cytoreductive Surgery and HIPEC. Annals of Surgical Oncology, 2020, 27, 4894-4907.	0.7	11
72	Impact of Neoadjuvant Chemotherapy on the Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases: A Multi-Institutional Retrospective Review. Journal of Clinical Medicine, 2020, 9, 748.	1.0	22

#	ARTICLE	IF	CITATIONS
73	Neoadjuvant Capecitabine/Temozolomide for Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors. <i>Pancreas</i> , 2020, 49, 355-360.	0.5	29
74	Pathologic complete response following neoadjuvant therapy for pancreatic ductal adenocarcinoma: defining the incidence, predictors, and outcomes. <i>Hpb</i> , 2020, 22, 1569-1576.	0.1	22
75	Surgical management of pancreatic neuroendocrine liver metastases. <i>Journal of Gastrointestinal Oncology</i> , 2020, 11, 590-600.	0.6	19
76	Institutional variation in recovery after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: An opportunity for enhanced recovery pathways. <i>Journal of Surgical Oncology</i> , 2020, 122, 980-985.	0.8	10
77	Transarterial Chemoembolization vs Radioembolization for Neuroendocrine Liver Metastases: A Multi-Institutional Analysis. <i>Journal of the American College of Surgeons</i> , 2020, 230, 363-370.	0.2	45
78	Dedicated Cancer Centers are More Likely to Achieve a Textbook Outcome Following Hepatopancreatic Surgery. <i>Annals of Surgical Oncology</i> , 2020, 27, 1889-1897.	0.7	41
79	Comparing textbook outcomes among patients undergoing surgery for cancer at U. S. News & World Report ranked hospitals. <i>Journal of Surgical Oncology</i> , 2020, 121, 927-935.	0.8	33
80	Assessment of textbook oncologic outcomes following pancreaticoduodenectomy for pancreatic adenocarcinoma. <i>Journal of Surgical Oncology</i> , 2020, 121, 936-944.	0.8	56
81	Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer: A Meta-Analysis of Randomized Controlled Trials. <i>Journal of Clinical Medicine</i> , 2020, 9, 1129.	1.0	83
82	Assessing Differences in Cancer Surgeon Approaches to Patient-Centered Decision-Making Using Vignette-Based Methodology. <i>Annals of Surgical Oncology</i> , 2020, 27, 2149-2156.	0.7	2
83	Influence of hospital teaching status on the chance to achieve a textbook outcome after hepatopancreatic surgery for cancer among Medicare beneficiaries. <i>Surgery</i> , 2020, 168, 92-100.	1.0	54
84	Repeat Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Is Not Associated with Prohibitive Complications: Results of a Multiinstitutional Retrospective Study. <i>Annals of Surgical Oncology</i> , 2020, 27, 4883-4891.	0.7	11
85	The Chicago Consensus on peritoneal surface malignancies: Management of appendiceal neoplasms. <i>Cancer</i> , 2020, 126, 2525-2533.	2.0	35
86	Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1588-1595.	0.5	15
87	Neoadjuvant therapy for resectable pancreatic ductal adenocarcinoma: The need for patient-centered research. <i>World Journal of Gastroenterology</i> , 2020, 26, 375-382.	1.4	12
88	Contemporary indications for and outcomes of hepatic resection for neuroendocrine liver metastases. <i>World Journal of Gastrointestinal Surgery</i> , 2020, 12, 159-170.	0.8	7
89	Neoadjuvant treatment strategies for intrahepatic cholangiocarcinoma. <i>World Journal of Hepatology</i> , 2020, 12, 693-708.	0.8	46
90	Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 556-563.	2.3	26

#	ARTICLE	IF	CITATIONS
91	ASO Author Reflections: Advances in the Multidisciplinary Management of Intrahepatic Cholangiocarcinoma. <i>Annals of Surgical Oncology</i> , 2020, 27, 2866-2867.	0.7	2
92	Treatment of neuroendocrine liver metastases: a patent landscape review. <i>Pharmaceutical Patent Analyst</i> , 2020, 9, 29-32.	0.4	0
93	Current Approaches in the Management of Hepatic Adenomas. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 199-209.	0.9	21
94	Validation of early drain removal after pancreatoduodenectomy based on modified fistula risk score stratification: a population-based assessment. <i>Hpb</i> , 2019, 21, 1303-1311.	0.1	16
95	Propensity Score Matching. <i>Journal of the American College of Surgeons</i> , 2019, 229, 436-437.	0.2	0
96	A Multi-institutional International Analysis of Textbook Outcomes Among Patients Undergoing Curative-Intent Resection of Intrahepatic Cholangiocarcinoma. <i>JAMA Surgery</i> , 2019, 154, e190571.	2.2	149
97	Perioperative Morbidity of Gastrectomy During CRS-HIPEC: An ACS-NSQIP Analysis. <i>Journal of Surgical Research</i> , 2019, 241, 31-39.	0.8	9
98	Primary Tumor Sidedness is Predictive of Survival in Colon Cancer Patients Treated with Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy: A US HIPEC Collaborative Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 2234-2240.	0.7	16
99	Impact of Neoadjuvant Chemotherapy on the Postoperative Outcomes of Patients Undergoing Liver Resection for Colorectal Liver Metastases: A Population-Based Propensity-Matched Analysis. <i>Journal of the American College of Surgeons</i> , 2019, 229, 69-77e2.	0.2	25
100	A national assessment of the utilization, quality and cost of laparoscopic liver resection. <i>Hpb</i> , 2019, 21, 1327-1335.	0.1	8
101	Impact of concomitant ablation on the perioperative outcomes of patients with colorectal liver metastases undergoing hepatectomy: a propensity score matched nationwide analysis. <i>Hpb</i> , 2019, 21, 1079-1086.	0.1	8
102	Disappearing liver metastases: A systematic review of the current evidence. <i>Surgical Oncology</i> , 2019, 29, 7-13.	0.8	30
103	Chemotherapy Versus Chemoradiation as Preoperative Therapy for Resectable Pancreatic Ductal Adenocarcinoma. <i>Pancreas</i> , 2019, 48, 216-222.	0.5	56
104	Staging for Ampullary Carcinoma: Is Less Actually More?. <i>Annals of Surgical Oncology</i> , 2019, 26, 1598-1600.	0.7	4
105	Duodenal adenocarcinoma: neoadjuvant and adjuvant therapy strategies. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 463-472.	0.5	1
106	Trends in centralization of surgical care and compliance with National Cancer Center Network guidelines for resected cholangiocarcinoma. <i>Hpb</i> , 2019, 21, 981-989.	0.1	38
107	The role of preoperative therapy prior to pancreatoduodenectomy for distal cholangiocarcinoma. <i>American Journal of Surgery</i> , 2019, 218, 145-150.	0.9	14
108	Population-Based Assessment of Selective Drain Placement During Pancreatoduodenectomy Using the Modified Fistula Risk Score. <i>Journal of the American College of Surgeons</i> , 2019, 228, 583-591.	0.2	7

#	ARTICLE	IF	CITATIONS
109	Laparoscopic synchronous resection of colorectal cancer and liver metastases: A systematic review. <i>Journal of Surgical Oncology</i> , 2019, 119, 30-39.	0.8	40
110	The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 101-108.	1.3	12
111	Minimally Invasive Surgery for Palliation. <i>Surgical Oncology Clinics of North America</i> , 2019, 28, 79-88.	0.6	4
112	Population level outcomes and costs of single stage colon and liver resection versus conventional two-stage approach for the resection of metastatic colorectal cancer. <i>Hpb</i> , 2019, 21, 456-464.	0.1	15
113	Early Morbidity and Mortality after Minimally Invasive Liver Resection for Hepatocellular Carcinoma: a Propensity-Score Matched Comparison with Open Resection. <i>Journal of Gastrointestinal Surgery</i> , 2019, 23, 1435-1442.	0.9	21
114	Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection. <i>Surgery</i> , 2019, 165, 657-663.	1.0	16
115	Predictors of Readmission After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. <i>Journal of Surgical Research</i> , 2019, 234, 103-109.	0.8	15
116	Patterns of readmission among the elderly after hepatopancreatobiliary surgery. <i>American Journal of Surgery</i> , 2019, 217, 413-416.	0.9	10
117	The impact of somatic SMAD4 mutations in colorectal liver metastases. <i>Chinese Clinical Oncology</i> , 2019, 8, 52-52.	0.4	8
118	Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma. <i>World Journal of Gastroenterology</i> , 2019, 25, 3704-3721.	1.4	107
119	Guidelines Insights: Hepatobiliary Cancers, Version 2.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 302-310.	2.3	214
120	What is the Incidence of Malignancy in Resected IPMN? An Analysis of Over 100 U.S. Institutions in a Single Year. <i>Annals of Surgical Oncology</i> , 2018, 25, 1797-1798.	0.7	3
121	Diagnostic and therapeutic implications of novel peptides in hepatocellular carcinoma. <i>Hepatology</i> , 2018, 68, 1223-1225.	3.6	0
122	Preoperative Fluorouracil, Doxorubicin, and Streptozocin for the Treatment of Pancreatic Neuroendocrine Liver Metastases. <i>Annals of Surgical Oncology</i> , 2018, 25, 1709-1715.	0.7	32
123	Minimally invasive hepatopancreatobiliary surgery: Where do we go from here?. <i>Surgical Oncology</i> , 2018, 27, A2-A4.	0.8	3
124	Two-Stage Hepatectomy vs One-Stage Major Hepatectomy with Contralateral Resection or Ablation for Advanced Bilobar Colorectal Liver Metastases. <i>Journal of the American College of Surgeons</i> , 2018, 226, 825-834.	0.2	34
125	Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. <i>Cancer</i> , 2018, 124, 1701-1709.	2.0	35
126	Lymphadenectomy for Intrahepatic Cholangiocarcinoma: Has Nodal Evaluation Been Increasingly Adopted by Surgeons over Time? A National Database Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 668-675.	0.9	55

#	ARTICLE	IF	CITATIONS
127	Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Biliary Tract Cancers Associated with Lynch Syndrome. <i>Journal of Gastrointestinal Cancer</i> , 2018, 49, 93-96.	0.6	29
128	Impact of Synchronous Liver Resection on the Perioperative Outcomes of Patients Undergoing CRS-HIPEC. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 1576-1584.	0.9	13
129	SMAD4 gene mutation predicts poor prognosis in patients undergoing resection for colorectal liver metastases. <i>European Journal of Surgical Oncology</i> , 2018, 44, 684-692.	0.5	61
130	Impact of Post-Discharge Disposition on Risk and Causes of Readmission Following Liver and Pancreas Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 1221-1229.	0.9	20
131	Hospital Teaching Status and Medicare Expenditures for Hepato-Pancreato-Biliary Surgery. <i>World Journal of Surgery</i> , 2018, 42, 2969-2979.	0.8	30
132	Portal Vein Embolization Reduces Postoperative Hepatic Insufficiency Associated with Postchemotherapy Hepatic Atrophy. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 60-67.	0.9	14
133	Liver resection is justified for patients with bilateral multiple colorectal liver metastases: A propensity-score-matched analysis. <i>European Journal of Surgical Oncology</i> , 2018, 44, 122-129.	0.5	20
134	Clinical features and survival of gastric cancer patients with DNA mismatch repair deficiency. <i>Journal of Surgical Oncology</i> , 2018, 117, 707-709.	0.8	1
135	Anthropometric Changes in Patients with Pancreatic Cancer Undergoing Preoperative Therapy and Pancreatoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 703-712.	0.9	39
136	Role of associating liver partition and portal vein ligation in staged hepatectomy (ALPPS) strategy for colorectal liver metastases. <i>Translational Gastroenterology and Hepatology</i> , 2018, 3, 66-66.	1.5	10
137	Pre-operative Sarcopenia Identifies Patients at Risk for Poor Survival After Resection of Biliary Tract Cancers. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 1697-1708.	0.9	50
138	Emerging treatment options for cholangiocarcinoma. <i>Expert Opinion on Orphan Drugs</i> , 2018, 6, 527-536.	0.5	3
139	Independent Predictors of Increased Operative Time and Hospital Length of Stay Are Consistent Across Different Surgical Approaches to Pancreatoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 1911-1919.	0.9	21
140	Clinical significance and prognostic relevance of KRAS, BRAF, PI3K and TP53 genetic mutation analysis for resectable and unresectable colorectal liver metastases: A systematic review of the current evidence. <i>Surgical Oncology</i> , 2018, 27, 280-288.	0.8	132
141	The Impact of Discharge Timing on Readmission Following Hepatopancreatobiliary Surgery: a Nationwide Readmission Database Analysis. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 1538-1548.	0.9	14
142	The relationship of hospital market concentration, costs, and quality for major surgical procedures. <i>American Journal of Surgery</i> , 2018, 216, 1037-1045.	0.9	2
143	The Cost of Failure: Assessing the Cost-Effectiveness of Rescuing Patients from Major Complications After Liver Resection Using the National Inpatient Sample. <i>Journal of Gastrointestinal Surgery</i> , 2018, 22, 1688-1696.	0.9	17
144	Adjuvant antiviral therapy for the prevention of hepatocellular carcinoma recurrence after liver resection: indicated for all patients with chronic hepatitis B?. <i>Annals of Translational Medicine</i> , 2018, 6, 397-397.	0.7	3

#	ARTICLE	IF	CITATIONS
145	Hammer versus Swiss Army knife: Developing a strategy for the management of bilobar colorectal liver metastases. <i>Surgery</i> , 2017, 162, 12-17.	1.0	12
146	Proton beam radiation as salvage therapy for bilateral colorectal liver metastases not amenable to second-stage hepatectomy. <i>Surgery</i> , 2017, 161, 1543-1548.	1.0	25
147	Selective Perioperative Administration of Pasireotide is More Cost-Effective Than Routine Administration for Pancreatic Fistula Prophylaxis. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 636-646.	0.9	39
148	Update on current problems in colorectal liver metastasis. <i>Current Problems in Surgery</i> , 2017, 54, 554-602.	0.6	39
149	Clinical and Genetic Implications of DNA Mismatch Repair Deficiency in Patients With Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2017, 152, 1086.	2.2	25
150	Neutrophil-to-lymphocyte ratio predicts prognosis after neoadjuvant chemotherapy and resection of intrahepatic cholangiocarcinoma. <i>Surgery</i> , 2017, 162, 752-765.	1.0	35
151	Association of Clinical Factors With a Major Pathologic Response Following Preoperative Therapy for Pancreatic Ductal Adenocarcinoma. <i>JAMA Surgery</i> , 2017, 152, 1048.	2.2	82
152	Influence of Preoperative Therapy on Short- and Long-Term Outcomes of Patients with Adenocarcinoma of the Ampulla of Vater. <i>Annals of Surgical Oncology</i> , 2017, 24, 2031-2039.	0.7	30
153	Impact of pancreatectomy on long-term patient-reported symptoms and quality of life in recurrence-free survivors of pancreatic and periampullary neoplasms. <i>Journal of Surgical Oncology</i> , 2017, 115, 144-150.	0.8	28
154	Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 164-174.	0.9	124
155	Predictors of readmission to non-index hospitals after colorectal surgery. <i>American Journal of Surgery</i> , 2017, 213, 18-23.	0.9	34
156	Role of Fluorouracil, Doxorubicin, and Streptozocin Therapy in the Preoperative Treatment of Localized Pancreatic Neuroendocrine Tumors. <i>Journal of Gastrointestinal Surgery</i> , 2017, 21, 155-163.	0.9	34
157	Duodenal adenocarcinoma: Advances in diagnosis and surgical management. <i>World Journal of Gastrointestinal Surgery</i> , 2016, 8, 212.	0.8	67
158	Impact of hypofractionated and standard fractionated chemoradiation before pancreatoduodenectomy for pancreatic ductal adenocarcinoma. <i>Cancer</i> , 2016, 122, 2671-2679.	2.0	49
159	Neuroendocrine tumors of the pancreas: Degree of cystic component predicts prognosis. <i>Surgery</i> , 2016, 160, 708-713.	1.0	42
160	Preoperative Chemoradiation for Pancreatic Adenocarcinoma Does Not Increase 90-Day Postoperative Morbidity or Mortality. <i>Journal of Gastrointestinal Surgery</i> , 2016, 20, 1975-1985.	0.9	42
161	Is weekend discharge associated with hospital readmission?. <i>Journal of Hospital Medicine</i> , 2015, 10, 731-737.	0.7	15
162	Association Between Weekend Discharge and Hospital Readmission Rates Following Major Surgery. <i>JAMA Surgery</i> , 2015, 150, 849.	2.2	26

#	ARTICLE	IF	CITATIONS
163	Does the Extent of Resection Impact Survival for Duodenal Adenocarcinoma? Analysis of 1,611 Cases. <i>Annals of Surgical Oncology</i> , 2015, 22, 573-580.	0.7	61
164	Acute Gastric Dilation and Necrosis as a Late Complication Following Laparoscopic Nissen Fundoplication. <i>Digestive Diseases and Sciences</i> , 2015, 60, 32-34.	1.1	4
165	Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management. <i>World Journal of Gastroenterology</i> , 2015, 21, 9512.	1.4	99
166	Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 637-644.	1.1	44
167	Early Vein Reconstruction and Right-to-Left Dissection for Left-Sided Pancreatic Tumors with Portal Vein Occlusion. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 2034-2037.	0.9	2
168	Postoperative Serum Amylase Predicts Pancreatic Fistula Formation Following Pancreaticoduodenectomy. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 348-353.	0.9	47
169	Does Chronic Kidney Disease Affect Outcomes after Major Abdominal Surgery? Results from the National Surgical Quality Improvement Program. <i>Journal of Gastrointestinal Surgery</i> , 2014, 18, 605-612.	0.9	59
170	Gastrointestinal Mucormycosis Initially Manifest as Hematochezia from Arterio-Enteric Fistula. <i>Digestive Diseases and Sciences</i> , 2014, 59, 2905-2908.	1.1	0
171	Indocyanine green and fluorescence lymphangiography for sentinel lymph node identification in cutaneous melanoma. <i>Journal of Surgical Oncology</i> , 2014, 110, 888-892.	0.8	51
172	Poor compliance with breast cancer treatment guidelines in men undergoing breast-conserving surgery. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 177-182.	1.1	14
173	Outcomes of Partial Mastectomy in Male Breast Cancer Patients: Analysis of SEER, 1983-2009. <i>Annals of Surgical Oncology</i> , 2013, 20, 1545-1550.	0.7	66
174	Preoperative embolization of replaced right hepatic artery prior to pancreaticoduodenectomy. <i>Journal of Surgical Oncology</i> , 2012, 106, 509-512.	0.8	23
175	Video-assisted thoracoscopic transdiaphragmatic liver resection for hepatocellular carcinoma. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2012, 26, 1772-1776.	1.3	14